iPSC-Derived Natural Killer Cells as the Front-Runner Program of the EVOcells Oncology Platform: From Inception to Translational Validation Using Patient Samples
In this poster we focus on:
- Development of robust feeder-free 3D differentiation protocol to reduce iNK cells
- Transnational validation of iNK functionality with freshly isolated CLL patient tumor cells
- Enhances CLL patient tumor cell killing with CAR19 iNK
- EVOcells Oncology programs